Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics, a biopharmaceutical company, has appointed Evelyn Graham as its new CEO and as a member of its board of directors. Ms Graham had been serving as the company's acting CEO since September 1, 2008.
Subscribe to our email newsletter
Ms Graham joined TorreyPines in 2004 as vice president of development. Ms Graham was then promoted to vice president of corporate development in 2005, COO in 2006 and acting CEO in September 2008.
Prior to joining TorreyPines Ms Graham was executive director of development operations at Purdue Pharma from 2000 to 2003. Ms Graham holds a BA in biology from the University of Delaware and an MBA from the University of Connecticut.
Peter Davis, chairman of the board of directors at TorreyPines, said: “We are delighted that she has agreed to become CEO and a member of the board at a time when TorreyPines is completing important clinical trials that hold promise for the company’s future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the company in meeting its strategic objectives.”